Skip to main content

Postgraduate Course in Cardiometabolic Medicine 2024

London, UK
Type of event
on site


Now Day Tickets Available!

Dear Colleagues

It is a pleasure to announce a truly innovative Postgraduate Course in Cardiometabolic Medicine, a timely and highly acclaimed educational programme conceived by Zurich Heart House – London Heart House, King’s College, and Royal Brompton & Harefield Hospitals, which will address an unmet educational need.

Cardiometabolic disorders represent a cluster of interrelated risk factors, primarily dyslipidemia, hypertension, elevated fasting blood glucose, obesity and non-alcoholic steatohepatitis. A combination of several of these risk factors massively increases the incidence and mortality of coronary heart disease and stroke. The strong association between metabolic disorders and cardiovascular health delivers a compelling reason to improve awareness of this cluster by identifying the risk factors and inducing targeted interventions.

The Postgraduate Course in Cardiometabolic Medicine consists of a four-day programme. State of the art lectures alternate with a great variety of interactive sessions, including workshops, rapid fire sessions and hands-on imaging sessions.

The course offers a unique opportunity to become one of the first experts in the seminal area of cardiometabolic medicine. We are looking forward to receiving your application and meeting you in London.


Andrew Krentz
Thomas F. Lüscher
Naveed Sattar
John Deanfield
Mahmoud Barbir
Michael Papadakis


Scientific Programme

Tuesday, April 30th, 2024 (UK time)

Venue: The Royal Society of Medicine

08:30 | Opening Session
08:30 Welcome by the course directors   
08:45 Course concept and structure  


09:00 | Session 1: Obesity I- Causes and mechanisms
Chairs: John E. Deanfield & Michael Papadakis
09:00 Is obesity a disease? If so, how do we diagnose? Francesco Rubino, London
09:20 The gut microbiome: a new risk factor for obesity and CVD Thomas F. Lüscher, London
09:40 Obesity and inflammation Marc Donath, Basel
10:00 What links adiposity to CVD?   Naveed Sattar, Glasgow
10:20 Panel discussion  
11:00 | COFFEE  


11:30 | Session 2: Obesity II – Management
Chairs: Naveed Sattar & Thomas F. Lüscher
11:30 Bariatric surgery: is there still a role? Barbara McGowan, London
11:50 Behavioural management: Nutrition Michael Lean, Glasgow
12:10 Behavioural management: Exercise & sports – ESC guidelines 2020 and beyond Michael Papadakis, London
12:30 Medical management of obesity: GLP-1/GIP agonists John E. Deanfield, London
12:50 Panel discussion  


14:30 | Session 3: ASCVD Assessment I
Chairs: Mahmoud Barbir & Thomas F. Lüscher
14:30 Inflammation and plaque formation Christian Weber, Munich
14:50 LDL-C and cardiovascular disease: Why is lower better? Lale Tokgozolu, Ankara
15:10 Cardiovascular risk assessment: the ESC SCORE/SCORE2-OP
The ESC Guidelines
Frank Visseren, Utrecht
15:30 Lifetime risk: CVD prevention - personal and national strategy John E. Deanfield, London
15:50 Panel discussion  
16:30 | COFFEE  
17:00 | Case-based interactive seminars  
  How to assess adiposity: Clinical, MRI and beyond Geltrude Mingrone, London
  How to manage obesity Barbara McGowan, London
18:00 | End of day 1  


Wednesday, May 1st, 2024

09:00 | Session 4: ASCVD Assessment II
Chairs:John Chapman & Christian Heiss
09:00 Multimodality imaging to assess ASCVD Chrsitoph Gräni, Bern
09:20 CT-based coronary imaging for CV risk prediction Charalambos Antoniades, Oxford
09:40 Novel lipoproteins: Lipoprotein(a) Francois Mach, Geneva
10:00 Are triglycerides a cardiovascular risk factor? Borge Nordestgaard, Copenhagen
10:20 Panel discussion  
11:00 | COFFEE  


11:30 | Session 5: ASCVD - Management
Chairs: Jürg H. Beer & Francois Mach
11:30 Secondary hypertension: an underrecognized condition    Tomasz Guzik, Edinburgh
11:50 Unsaturated fatty acids and CV risk reduction    John Chapman, Paris
12:10 Personalized LDL-C management: From pills to nucleic acids Kausik Ray, London
12:30 Arterial hypertension: from drugs to devices Vikas Kapil, London
12:40 Panel discussion  
14:30 | Hands-on seminars  
  Practical lipid apheresis Mahmoud Barbir, London / Jo Senior, Harefield / Alison Pottle, Harefield / Stefan Bornstein, Dresden
  Assessing vascular structure and function - practical demonstrations Christian Heiss, Guildford
16:30 | COFFEE


17:00 | Session 6 ASCVD: Platelets and coagulation 
Chairs:Thomas F. Lüscher & Shouvik Haldar
17:00 Intravascular thrombus formation: platelets and intrinsic/extrinsic system Jürg H. Beer, Baden
17:20 Platelet inhibition: DAPT or SAPT? (the 2023 ESC guidelines on ACS) Robert Byrne, Dublin
17:40 Novel oral anticoagulants in VTE and AF: the ESC Guidelines and beyond A. John Camm, London
18:00 Panel discussion  


Thursday, May 2nd, 2024

09:00 | Session 7: Diabetes mellitus (DM)
Chairs: Andrew Krentz & Stephan Jacob
09:00 Pathogenesis of Type 2 DM Marc Donath, Basel
09:20 Diabetes Type 2 and CVD beyond glucocentricity    Stephan Jacob, Villingen
09:40 Management of CVD risk in type 2 diabetes –
the 2023 ESC Diabetes guidelines
Dirk Müller-Wieland, Aachen
10:00 Panel discussion  
10:30 | COFFEE  


11:00 | Session 8: Nephrology - Chronic kidney disease (CKD) – Causes & Mechanisms
Chairs: Joao Pedro Ferreira & Andrew Krnetz
11:00 Causes and clinical presentation of CKD Britta George. Zurich
11:20 CKD and cardiovascular risk Thimoteus Speer, Frankfurt
11:40 Albuminuria, eGFR slopes and outcomes: impact of pharmacotherapy

David Wheeler, London

12:00 Panel discussion  

Industry Sponsored Symposium:
Challenging the Status Quo in Cardiorenal Management

This is a promotional symposium sponsored and organised by AstraZeneca, intended for GB HCPs only



14:00 | Session 9: Nephrology - Chronic kidney disease (CKD) - Management
Chairs: Thimoteus Speer & Britta George
14:00 SGLT2i and GLP1-RA bin CKD and DKD – the 4 pillar approach Christoph Wanner, Würzburg (remote)
14:20 Non-steroidal MR antagonists Bertram Pitt, An Arbor (remote)
14:40 Management of hyperkalemia in CKD and HFrEF Joao Pedro Ferreira, Porto
15:00 Panel discussion  
15:30 | COFFEE  
16:00 | Case-based interactive seminars  
  Managing type 2 diabetes and CVD risk Stephan Jacob, Villingen
  Managing patients with CKD Timo Speer, Frankfurt
17:00 | End of day 3  


Friday, May 3rd, 2024

09:00 | Session 10: Metabolic dysfunction-associated steatotic liver disease (MASLD) and Endocrinology
Chairs: Andrew Krentz & Kamlesh Khunti
09:00 Screening and diagnosis of MASLD Philip Newsome, Birmingham
09:20 Extrahepatic cardiometabolic disease associations with MASLD Kevin Moore, London
09:40 Management of MASLD    William Alazawi, London
10:00 Cardiovascular risk in endocrine disease Adrian Heald, Manchester
10:20 Sex hormones Andrew Krentz, London
10:40 Panel discussion  
11:00 | COFFEE  


11:30 | Session 11: Amyloid heart disease
Chairs: Rakesh Sharma & Eleanor Wicks
11:30 The spectrum of amyloid heart disease Ashutosh Wechalekar, London
11:50 Diagnosis and management of cardiac amyloidosis Roy S. Gardner, Glasgow
12:10 Panel discussion  


13:30 | Session 12: Heart failure
Chairs: Roy Gardner & Rajdeep Khattar
13:30 Prevention of heart failure Pardeep Jhund, Glasgow
13:50 The different forms of heart failure Aigul Baltabaeva, London
14:10 Comorbidities of heart failure Michele Senni, Bergamo
14:30 Iron deficienca nd heart failure Paul Kalra, Portsmouth
14:50 Management of heart failure: the 2021 and 2023 ESC guidelines    Theresa McDonagh, London
15:10 Panel discussion  
15:30 | COFFEE  
16:00 | Hands-on seminars  
  Diagnosing MASLD with FibroScan Kevin Moore, London
  Diagnosing heart failure with echocardiography Rajdeep Khattar, London
17:00 | End of day 4  


The programme may be subject to change.


Industry Sponsored Symposium

Thursday, May 2nd, 2024

12:30 Challenging the Status Quo in Cardiorenal Management
This is a promotional symposium sponsored and organised by AstraZeneca, intended for GB HCPs only.
Speakers: Professor Derek Connolly, BSc[Hons] MB ChB[Edin] PhD[Cantab] DSc[Hon] FRCP FRCPE FESC, Consultant Cardiologist, Birmingham City & Sandwell Hospitals
  Dr Kate Bramham, Reader of Nephrology & Maternal Medicine and Honorary Consultant Nephrologist, King’s College London

General Information


Registration fees  
Regular fee GBP 950
Early registration fee (until March 1, 2024) GBP 850
Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)* GPB 700

*For the reduced registration (Trainees/Residents, Research fellows, Nurses, Students <40 years) please send a copy of your ID to Ms. Christine Lohmann at

Registration will be confirmed upon receipt of payment.
Please note that UK banks may charge high fees for international bank transfers. We therefore recommend payment by credit card.

Modification & Cancellation

All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to Zurich Heart House. For each modification requested by the participant, GBP 15 will be charged for administrative costs. In case of cancellation up to March 31st, 2024, deposits will be refunded less 35% for administrative costs. After this date, no refund will be possible.


The Royal Society of Medicine,
1 Wimpole St, Marylebone, London W1G 0AE, United Kingdom



Zurich Heart House, Foundation for Cardiovascular Research
Dr. Ruth Amstein
Christine Lohmann
Hottingerstrasse 14, CH-8032 Zurich, Switzerland
Phone +41 (0) 44 250 40 95, Fax +41 (0) 44 250 40 90



The Postgraduate Course in Cardiometabolic Medicine has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 26 category 1 (external) CPD credit(s).

The Postgraduate Course in Cardiometabolic Medicine has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for a maximum of 26 European CME Credits (ECMECs).


Teaching Faculty

William Alazawi
Queen Mary University of London
London, UK

Britta George
University hospital Zurich
Zurich CH

Charalambos Antoniades
University of Oxford
Oxford, UK

Roy S. Gardner
Golden Jubilee National Hospital
Clydebank/Glasgow, UK

Aigul Baltabaeva
Royal Brompton & Harefield Hospitals
London, UK

Christoph Gräni
Bern, CH

Mahmoud Barbir
Royal Brompton & Harefield Hospitals
London, UK

Tomasz Guzik
University of Edinburgh
Edinburgh, UK

Hans-Jürg Beer
Cantonal hospital Baden
Baden, CH

Shouvik Haldar
Royal Brompton & Harefield Hospitals
London, UK

Stefan Bornstein
University hospital Dresden
Dresden, DE

Adrian Heald
University of Manchester
Manchester, UK

Kate Bramham
King’s College London
London, UK    

Christian Heiss
University of Surrey
Guildford, UK

Robert Byrne
Mater Private Network Dublin Hospital
Dublin, IE

Stephan Jacob
Practice for prevention and therapy
Villingen-Schwenningen, DE

A. John Camm
St. George’s University Hospital
London, UK

Pardeep Jhund
University of Glasgow
Glasgow, UK

John Chapman
Hôpital de la Pitié
Paris, FR

Paul Kalra
Portsmouth Hospitals NHS Trust
Portsmouth, UK

Derek Connolly
Birmingham City & Sandwell Hospitals
Birmingham, UK

Vikas Kapil
Queen Mary University of London
London, UK

John E. Deanfield
University College London
London, UK

Rajdeep Khattar
Royal Brompton & Harefield Hospitals
London, UK

Marc Donath
University hospital Basel
Basel, CH

Kamlesh Khunti
University of Leicester
Leicester, UK

João Pedro Ferreira
University of Porto
Porto, PT

Andrew Krentz
King’s College London
London, UK

Michael Lean
University of Glasgow
Glasgow, UK

Francesco Rubino
King’s College London
London UK

Thomas F. Lüscher
Royal Brompton & Harefield Hospitals
London, UK

Naveed Sattar
University of Glasgow
Glasgow, UK

François Mach
University hospital Geneva,
Geneva, CH

Joanne Senior
Royal Brompton & Harefield Hospitals
Harefield, UK

Theresa McDonagh
King’s College Hospital
London, UK

Michele Senni
ASST Papa Giovanni XXIII Hospital
Bergamo, IT

Kevin Moore
University College London
London, UK    

Rakesh Sharma
Royal Brompton & Harefield Hospitals
London, UK

Barbara McGowan
Guy's and St Thomas' NHS Foundation Trust
London, UK

Thimoteus Speer
Goethe- University
Frankfurt am Main, DE

Geltrude Mingrone
King's College London
London, UK

Lale Tokgözoğlu
Hacettepe University
Ankara, TR

Dirk Müller-Wieland
University hospital Aachen
Aachen, DE

Frank L.J. Visseren
Utrecht Medical Center
Utrecht, NL

Philip Newsome
University of Birmingham
Birmingham, UK

Christoph Wanner
University hospital Würzburg
Würzburg, DE

Børge Nordestgaard
Copenhagen University Hospital
Copenhagen, DK    

Christian Weber
Ludwig-Maximilians-University Munich
Munich, DE

Michael Papadakis
St. George’s University Hospitals
London, UK    

Ashutosh Wechalekar
Royal Free Hospital
London, UK

Bertram Pitt
University of Michigan
Ann Arbor, US    

David C. Wheeler
University College London
London, UK

Alison Pottle
Royal Brompton & Harefield Hospitals
Harefield, UK

Eleanor Wicks
University of Oxford
Oxford, UK

Kausik Ray
Imperial College London
London, UK   


This meeting has been sponsored by AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo UK, Novartis and Pfizer. These companies have had no input or influence on the agenda, content of this meeting including the selection of speakers.

Under the Auspices of

In collaboration with